Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation
Recruiting
N/A
Interventional Study
Endometrial Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 45 and older
- Sex
- Female
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 735 (estimated)
- Sponsor
- Radboud University Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Rationale: Preoperative identification of patients at risk for lymph node metastasis (LNM) is challenging in endometrial cancer (EC). Therefore, a Bayesian network model called ENDORISK was developed and validated in three external cohorts to improve preoperative risk stratification. The next step is to implement and evaluate whether use of the model improves daily clinical practice. Objective: Th…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosed with early stage (FIGO stage I-II) endometrial carcinoma (every grade permitted)
* Eligible for primary surgical treatment (neo-adjuvant therapy is permitted)
Exclusion Criteria:
* Unable to give informed consent
* No understanding of Dutch or English language
* Ra…
Contacts